Amarin Corp Plc (AMRN)

[Southpacificislander]

Couldbebetter,

Obviously, requesting a retraction is not in Amarin’s DNA, nor did it consider this possibility or want to bother the cardiologist community. Whatever the reason, there is a huge need for this retraction, and Amarin should wake up. If not, we should wake Amarin up. But How? Does anyone have a contact with Sarissa?

Or, is Sarissa unconcerned with the current price in order to implement its buyback strategy for a maximized accretive effect during an acquisition?

I thought the annual price set in England was around 2000 euros. Am I wrong? There are 6 million patients in Europe only for secondary prevention. We agree that the market is huge, which stands in stark contrast to Amarin's valuation.